Pharmaceuticals

The 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard

HOUSTON, March 10, 2026 /PRNewswire/ -- While exotoxins dominate discussions of bacterial infections, endotoxins—cell wall components released upon bacterial death—are equally dangerous. These endotoxins trigger hyperinflammatory responses that spiral into endotoxemia, in which bloodstream endoto...

2026-03-10 15:22 3668

Codex Genetics Partners with C2N Diagnostics to Introduce the PrecivityAD2™ Blood Test in Hong Kong, Facilitating Access to Innovative Alzheimer's Disease Diagnostics

HONG KONG, March 10, 2026 /PRNewswire/ -- Codex Genetics, a leading precision diagnostics company headquartered in Hong Kong, today announces a strategic collaboration with C2N Diagnostics (C2N), a global leader in in advanced brain health diagnostics. The partnership will introduce the Precivit...

2026-03-10 09:33 5320

Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China

SHANGHAI, March 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the commercial launch of VELSIPITY® (...

2026-03-09 21:27 8643

Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis

CHENGDU, China, March 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug ...

2026-03-09 19:39 5575

IgHM - A New Breakthrough in Immunonutrition

HO CHI MINH CITY, Vietnam, March 9, 2026 /PRNewswire/ -- With an orientated development based on scientific nutrition, VitaDairy (Vietnam) has officially introduced its new ColosBaby Lactoferrin - a nutritional formula, which is utilized with many superior nutrients such as a super-immune complex...

2026-03-09 19:13 3715

G-NiiB GenieBiome and Ocean Park Conclude Gut Microbiome Education Programme

Two–Year Initiative Reaches Over 200,000 Parents and Children Student Artworks Reflect Early Understanding of Gut Health HONG KONG, March 9, 2026 /PRNewswire/ -- The gut is responsible for more than digestion and is often described as the body's "second brain." Research in recent years has highli...

2026-03-09 17:10 4376

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 9, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Kelun-Biotech (6990.HK) today announced ...

2026-03-09 16:32 6154

Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer

NANJING, China, March 9, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK)announced on March 6, 2026 that the first patient has been successfully dosed in a Phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company's core inve...

2026-03-09 14:28 4626

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

* Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs.  * Transaction represents total equity value of approximately $2.5 billion. SURESNES, France and BRISBANE, Calif., Marc...

2026-03-07 02:30 11958

CARsgen Therapeutics Announces 2025 Annual Results

SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results. Business Highlights * Cash and cash equivalents were around RMB1,123 million as of Decemb...

2026-03-06 20:03 9952

Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial

CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia previou...

2026-03-06 18:53 6464

Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Chronic Weight Management

HANGZHOU, China, March 6, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National Medical Products Administration (NMPA) has ...

2026-03-06 14:39 4231

Cerecin Announces TEDx Talk by CEO Dr. Charles Stacey is Now Available Online

Titled "The Potential of Fasting and Diet in the Future of Medicine" Highlighting the Potential of Ketones - from Fasting, the Ketogenic diet and Pharmaceuticals - to Address Neurological Disease and Improve Brain Health DENVER, Colo., March 5, 2026 /PRNewswire/ -- Cerecin Inc., a clinical-stage ...

2026-03-05 22:28 3927

Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results

HONG KONG, March 4, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II study (COMPASSION-03/AK104-201) of cadonilimab as a monotherapy for patients with recurrent or metasta...

2026-03-05 10:26 7654

Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference

TAIPEI, March 4, 2026 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced its participation in the 2026 International Patient and Scientific Conference hosted by the Kennedy's Disease Association (KDA). Held between February 27 and March 2, the conference served as a prem...

2026-03-05 09:47 4936

Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

* Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer * Novel combination therapy will be studied as part of the Phase II adaptive pl...

2026-03-04 21:52 7650

MGI Tech Announces Acquisition of STOmics and CycloneSEQ to Deliver Integrated Long-Read, Short-Read and Spatial Omics Solutions

SHENZHEN, China, March 4, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in the life sciences, today announced the acquisition of STOmics and CycloneSEQ. It marks a significant milestone in MGI's "SEQALL+GLI+Omi...

2026-03-04 11:58 5555

Gene Solutions Announces Strategic Entry into Türkiye with Robust Real-World Evidence at the 2nd International Hereditary Cancers Congress 2026

In Partnership with ATC Genomics, the Company Presented One of Asia's Largest Real-World Datasets (n=12,281) for AI-Powered Multi-Cancer Early Detection (MCED) and Showcased its Clinically Validated ctDNA-Powered Oncology Portfolio Across the Full Cancer Continuum for High-Risk and Hereditary Pop...

2026-03-04 10:00 8667

Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains

HOUSTON, March 3, 2026 /PRNewswire/ -- The World Health Organization (WHO) has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A(H3N2) subclade K and emerging B/Victoria lineage strains. In rapid response, Sin...

2026-03-04 09:53 6400

Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases

* Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases. * Antengene will receive USD 80 million of upfront and near-term milestone payments, and is e...

2026-03-04 06:00 5701
1 ... 13141516171819 ... 342

Week's Top Stories